MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
This study is testing an improved online tool called MySmartSkin (MSS) to help melanoma survivors check their skin for new or returning melanoma. It compares the enhanced MySmartSkin tool to a standard educational webpage about skin self-exams. The goal is to see which approach is more effective in helping people perform thorough skin self-exams and if it reduces new melanomas. You might be able to join if you've had melanoma (stages 0-III), are 18 or older, and haven't been checking your whole body for melanoma regularly. The study will measure how well participants examine their body parts at the start, and then again at 3 and 6 months.
- Study design
- This is a longitudinal randomized controlled trial (RCT) with 385 planned participants. It compares the enhanced MySmartSkin tool to an educational webpage.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for at least 6 months, with body parts examined measured at baseline, 3 months, and 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sharon Manne, PhD · PRINCIPAL_INVESTIGATOR · Rutgers Cancer Institute of New Jersey
- Carolyn Heckman, PhD · PRINCIPAL_INVESTIGATOR · Rutgers Cancer Institute of New Jersey
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Body parts examinedBaseline
Yes/No for a list of body parts examined during most recent SSE in the last three months. This is the primary outcome because SSE thoroughness is associated with detection of thinner tumors. This will be assessed by Reach, Effectiveness, Adoption, Implementation, and Maintenance(RE-AIM) and Practical, Robust Implementation and Sustainability Model (PRISM).
- Body parts examined3 months
Yes/No for a list of body parts examined during most recent SSE in the last three months. This is the primary outcome because SSE thoroughness is associated with detection of thinner tumors. This will be assessed by Reach, Effectiveness, Adoption, Implementation, and Maintenance(RE-AIM) and Practical, Robust Implementation and Sustainability Model (PRISM).
- Body parts examined6 months
Yes/No for a list of body parts examined during most recent SSE in the last three months. This is the primary outcome because SSE thoroughness is associated with detection of thinner tumors. This will be assessed by Reach, Effectiveness, Adoption, Implementation, and Maintenance(RE-AIM) and Practical, Robust Implementation and Sustainability Model (PRISM).
- Body parts examined12 months
Yes/No for a list of body parts examined during most recent SSE in the last three months. This is the primary outcome because SSE thoroughness is associated with detection of thinner tumors. This will be assessed by Reach, Effectiveness, Adoption, Implementation, and Maintenance(RE-AIM) and Practical, Robust Implementation and Sustainability Model (PRISM).
- Body parts examined18 months
Yes/No for a list of body parts examined during most recent SSE in the last three months. This is the primary outcome because SSE thoroughness is associated with detection of thinner tumors. This will be assessed by Reach, Effectiveness, Adoption, Implementation, and Maintenance(RE-AIM) and Practical, Robust Implementation and Sustainability Model (PRISM).